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Abstract
In this study, we analyzed the ABCD1 gene in X-linked adrenoleukodystrophy (X-ALD) patients and relatives from 38
unrelated families from South America, as well as phenotypic proportions, survival estimates, and the potential effect of
geographical origin in clinical characteristics.
Methods: X- ALD patients from Brazil, Argentina and Uruguay were invited to participate in molecular studies to determine
their genetic status, characterize the mutations and improve the genetic counseling of their families. All samples were
screened by SSCP analysis of PCR fragments, followed by automated DNA sequencing to establish the specific mutation in
each family. Age at onset and at death, male phenotypes, genetic status of women, and the effect of family and of latitude
of origin were also studied.
Results: We identified thirty-six different mutations (twelve novel). This population had an important allelic heterogeneity,
as only p.Arg518Gln was repeatedly found (three families). Four cases carried de novo mutations. Intra-familiar phenotype
variability was observed in all families. Out of 87 affected males identified, 65% had the cerebral phenotype (CALD). The
mean (95% CI) ages at onset and at death of the CALD were 10.9 (9.1–12.7) and 24.7 (19.8–29.6) years. No association was
found between phenotypic manifestations and latitude of origin. One index-case was a girl with CALD who carried an
ABCD1 mutation, and had completely skewed X inactivation.
Conclusions: This study extends the spectrum of mutations in X-ALD, confirms the high rates of de novo mutations and the
absence of common mutations, and suggests a possible high frequency of cerebral forms in our population.
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Introduction
X-linked adrenoleukodystrophy (X-ALD, OMIM #300100) is a
neurodegenerative disease characterized by great clinical expression
variability even within the same family. Several phenotypes are
recognized in males according to the age of onset, affected organs
and rate of the progression of neurologic symptoms. The X-ALD
clinical spectrum ranges from the rapidly progressive childhood
cerebral form (CALD), which typically leads to severe disability and
death duringthefirstdecade,to the milderadrenomyeloneuropathy
(AMN) that usually manifests between ages 20 and 30 years and
may be compatible with survival into the eighth decade, to pure
Addison’s disease [1]. Whereas AMN is characterized mainly by a
noninflammatory ‘‘dying-back’’ axonopathy, involving the long
spinal tracts, the inflammatory nature of the demyelinating lesion in
CALD resembles those found in multiple sclerosis (MS), the most
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ALD Mutations in South America
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34195commoncentraldemyelinative disease.It is postulated that modifier
genes or environmental factors are involved in the pathogenesis of
these highly variable phenotypes [1,2,3].
X-ALD is caused by a defect in the gene for the adenosine
triphosphate (ATP)-binding cassette protein, subfamily D, member
1 located on Xq28 (ABCD1) [1]. X-ALD protein (ALDP) [4], is a
structural protein related to the transport of very long chain fatty
acids (VLCFA) across peroxisome membranes. The ABCD1 gene
contains 10 exons, spanning 20 kb of genomic DNA and ALDP
contains 745 amino acids.
Since its identification, 1236 mutations have been reported in
the ABCD1 gene of which 582 (47%) appear to be private (http://
www.x-ald.nl). Mutations have been found throughout the entire
gene, but they are not distributed evenly. There is a clustering of
mutations in the transmembrane domain (47%), in the ATP-
binding domain (34%), and in exon 5 (8%), which is not part of
any of these domains. The remaining 11% of mutations are spread
throughout other parts of the gene. No promoter mutations or
complete gene deletions have been reported [5].
The main biochemical abnormality associated with X-ALD is
the accumulation of unbranched saturated VLCFA in plasma and
tissues, due to impaired b-oxidation in peroxisomes. The increase
in VLCFA levels provides a reliable diagnostic tool for prenatal
and postnatal identification of affected males. In females, however,
VLCFA levels present false-negative results in around 20% of the
obligate carriers [1]. Mutation analysis is therefore the best
approach in order to improve genetic counseling to the families.
X-ALD is the most common peroxisomal disorder with a
hemizygote frequency of 1:21,000 in USA [6] and of at least
1:35,000 in South Brazil [7]. Although no differences in
distribution of mutations were found among different populations
[5,8,9,10], little is known about differences in X-ALD epidemi-
ology in particular countries and continents. Specially, there is a
relative lack of knowledge about the X-ALD epidemiology on
subtropical regions of the world. This knowledge may not only
help these populations, but may also help the identification of
environmental factors that may modify X-ALD phenotype.
The present study aims to describe the ABCD1 mutations in a
case series of X-ALD families from South American patients, most
of them Brazilian individuals, the rate of de novo mutations,
phenotypes and survival estimates in the affected males found in
this population.
Materials and Methods
Ethics Statement
The present work has been approved by the Ethics Committee
from the institution at which the work was performed - Comissa ˜o
de E ´tica em Pesquisa do Hospital de Clı ´nicas de Porto Alegre -,
which follows the Code of ethics of the World Medical Association
(Declaration of Helsinki) and the standards established by the
author’s Institutional Review Board and granting agency. We have
obtained written informed consent from all participants involved
in the study.
Patients
Patients originated from Brazil, Argentina and Uruguay, were
previously diagnosed by VLCFA analysis. Most of them were
followed-up in the main institution where the present study was
carried out, while others were ascertained by their physicians in
other sites. Families received genetic counseling and appropriate
management, as described elsewhere [7]. These families were
invited to participate in the present study, which was approved by
the local Ethics Committee. Variables such as age, age at onset of
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34195symptoms, age at death, male phenotypes, genetic status (in
women, such as obligate carriers), the family and the latitude of
origin were also studied.
Methods
After written consent, blood was collected from the index-case
and DNA was extracted by the salting out procedure [11]. Using
10 PCR reactions it was possible to screen the entire coding
sequence of the ABCD1 gene and intron-exon boundaries using the
protocol described by Boehm et al [12]. All samples were screened
by single strand conformational polymorphism (SSCP) analysis
followed by automated DNA sequencing to establish the specific
mutation in each family. The different conditions used for SSCP
were: 6% and 8% polyacrilamide-agarose gel eletrophoresis(-
PAGE) at room temperature, 8% and 10% PAGE at 4uC. These
conditions were chosen at random. Amplicons with mobility shift
were purified with Exo-SAP (GE Healthcare) and submitted to
automated sequencing on ABI 3100 Genetic Analyzer using
BigDye v3.0 (Life Technologies). Mutations were confirmed by
reverse strand PCR sequencing. Pathogenicity of novel missense
mutations was assessed by in silico analysis using PolyPhen
(http://genetics.bwh.harvard.edu/pph/) and SIFT (http://sift.
jcvi.org) based on aminoacid sequence NP_000024. Family
relatives were screened for the specific mutation by PCR and
automated sequencing.
The percent of mutations assigned at each exon was compared
to those described in the literature at http://www.x-ald.nl.
(17.10.2011). The mutations were also mapped according to the
protein domains described by Kumar et al [13].
When an affected male was no longer available, an obligate
carrier or a female relative with elevated VLCFA was chosen as
the family’s index case.
Patient characteristics are given as mean 6 SD and range.
Categorical variables such as normal, homozygote women versus
heterozygote women were compared through chi-square test.
Kaplan-Meyer curves were used to describe survival until disease
onset, according to phenotypes, and to describe survival, in
CALD. All tests were 2-sided. Test results were considered
significant at the 0.05 level.
Results
From 2007 to 2011, thirty-eight families entered the study. Of
those, thirty-six were Brazilian families, 20 of them originating
from Rio Grande do Sul, the Southern most state of Brazil. The
clinical characteristics of some of these latter families have been
previously reported [7]. We have also recruited one family from
Uruguay and one family from Argentina to the present case series.
Twenty-four families lived around parallel 30th South (Capricorn
tropic), whereas 14 families lived between Equator and parallel
20th South.
Molecular results
Sequencing of the exons with mobility shift detected by SSCP,
revealed thirty-six different sequence variations in the 38 families
(Table 1). Twelve index-cases (or 31.5% of the total sample of
families) carried new mutations. The other 26 carried 24
mutations already described in the literature: 14 were missense
mutations and 10 were nonsense or frameshift mutations.
Insertion/deletion of one amino acid, or major deletions were
not detected among our patients.
The already described p.Arg518Gln mutation [14] was found in
three families from Rio Grande do Sul: one of these affected
families was due to a de novo mutation in the maternal germ line.
We can not rule out the possibility that the other two p.Arg518Gln
pedigrees have a common ancestral origin, given their geograph-
ical proximity. All the other detected mutations were found in
unique pedigrees.
Eight of the twelve new sequence variations were considered
pathogenic mutations due to the creation of premature stop codon
– either by nonsense mutation or as consequence of deletions,
insertions or duplication (Table 1). The remaining four novel
sequence variations (p.Pro623Leu, p.Leu628Glu, p.Ile481Phe and
p.Arg401Gly), if not causative of the disease, were linked to X-
ALD genotype by DNA study of hemizygous affected males.
PolyPhen analysis of the four novel missense mutations considered
three of them to be ‘‘probably damaging’’ p.Arg401Gly (PSIC
score 3.071), p.Pro623Leu (PSIC score 3.379), and p.Leu628Glu
(PSIC score 2.417), whereas p.Ile481Phe was considered ‘‘benign’’
Figure 1. Distribution of the mutations observed in this series according to the amplicon regions (exons), and compared with the
expected proportions (http://www.x-ald.nl).
doi:10.1371/journal.pone.0034195.g001
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not be tolerated.
The incidence of mutations in exons 1A and in exon 3 to 6 were
very similar to the reported in other populations (http://www.x-
ald.nl). There seemed to be less mutations than expected in exons
1B and 1C, where we found 8.4% and 5.5% of our cases versus
the expected 18% and 19%; and more mutations than expected in
exon 2, with 14% of observations versus the expected 4%, (http://
www.x-ald.nl) (Figure 1).
In 35 families, information on the genetic status of the oldest
transmitting mother was available. In this subset of families, we
were able to define four de novo mutations (Figure 2).
From the remaining 34 families where the mutation was
inherited, 21 men (2–53 years of age) and 77 women older than
18 years old were tested by molecular methods. Of those,
thirty-eight females (or 49%) and thirteen males (or 62%) of
the studied relatives also carried mutations. These proportions
were in accordance with a priori mendelian risks (chi-square
ns).
Clinical characteristics of the present sample
Index-cases comprised 30 males and 8 females - six obligate
carriers or biochemically proven heterozygotes, and two symp-
tomatic women.
Clinical characteristics of the affected men, index-cases as well
as the other affected relatives were described in Table 2. The
family history of up to three generations, plus biochemical and
molecular studies of the men alive identified 87 affected men in
these 38 genealogies. At the end of this investigation, 6
asymptomatic, 6 Addison-only, 54 CALD (27 already deceased),
and 14 AMN (3 already deceased) had been recognized. These
phenotypes were distributed among the families, with no peculiar
clustering in any pedigree (data no shown). Kaplan-Meyer curves
on age at onset of each phenotype, and on survival of the cerebral
Figure 2. The four pedigrees where de novo mutations were detected.
doi:10.1371/journal.pone.0034195.g002
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34195forms were presented in Figure 3. No differences on proportion of
phenotypes, on ages at onset or on survival (data not shown) of
CALD were seen, according to the latitude of origin of the affected
patient (Figure 3B and Table 1).
Twosymptomaticwomenwere the index-cases oftheirrespective
families. Case 55 was a 63 years old woman with a progressive, pure
spastic paraplegia and urinary incontinence with 10 years of disease
duration. There was no previous occurrence in the family. Her
VLCFA profile was highly suggestive of a heterozygous state for X-
ALD; the molecular analysis revealed the presence of the mutation
p.GLy510Ser in one of her alleles (Table 2).
Case 54 was a 15 years old girl with clinical, biochemical and
MRI abnormalities similar to those found in boys with the
childhood cerebral phenotype (Figure 4). Motor and cognitive
deterioration started at 6 years of age; VLCFA analysis was
compatible with the heterozygous state (C26:0 of 2.02, normal
range: 0.78 to 1.54; C26:0-C22:0 of 0.051, normal range: 0.01 to
0.03). She had completely skewed X-inactivation in blood cells, as
determined by the human androgen receptor locus (HUMARA)
methylation assay. Her G-banded karyotype was normal and the
array-comparative genome hybridization (a-CGH) analysis re-
vealed no X chromosome copy-number alterations (44K X-
chromosome platform, design 2008, Agilent Technologies, Santa
Clara, USA). Gene sequencing of this girl revealed the presence of
the mutation p.Ser358fsX42 in one of her alleles (Table 1),
probably on the active X chromosome.
Genotype/Phenotype relationships
Some families were considered informative regarding the
detected phenotypes: families with only CALD patients (more than
one CALD patient), and heterogeneous families (with at least one
CALD and one AMN). After that, the affecteddomainof the ALDP
was defined: only NBF (20 families) and TMD (10 families) domains
were considered. Distribution of these domains among the families
characterizedasCALDorheterogeneouswasequal (ns,chi-square).
Discussion
The present results probably describe the first case series of
South American mutations related to X-ALD. Although it is
usually said that all ethnic groups are affected by this disease, there
is scarce knowledge about differences in frequency of X-ALD
phenotypes or genotypes in our region, as well as in other
subtropical regions of the world. Our results suggest some
peculiarities such as a higher incidence of mutations in exons 2
and 8–9, and of cerebral forms, than the expected.
More than a thousand different mutations at ABCD1 gene have
been related to X-ALD. There are no common mutations for this
disease: the most recurrent in other reports was p.Gln472fsX555, a
frameshift mutation detected in 6.4% of cases recorded. At least
47% of all reported mutations have been found in single pedigrees
in the world (http://www.x-ald.nl). Our rate of 34% of new
mutations is in agreement with this overall picture, moreover if we
remember that even the only recurrent mutation in our case series
(p.Arg518Gln) has emerged at least once from a de novo
phenomenon (Table 1 and Figure 2).
We have found 4/35 de novo mutations, or 10% (Figure 2). In a
previous large series, the rate of the detected de novo mutations had
been of 5% in affected male probands [7]. The actual numbers
might be much higher, if at least three generations (up to the
grand-mothers) would be checked. The absence of any frequent
Figure 3. Kaplan–Meier survival curves. (A) Overall disease onset of the main phenotypes Addison-only, cerebral (CALD) and
adrenomyeloneuropathy (AMN). Disease onset were significantly different (log rank test, p,0.001). (B) Disease onset of CALD, according to latitude
of origin of the patient (ns). (C) CALD survival until death.
doi:10.1371/journal.pone.0034195.g003
Table 2. Clinical characteristics of the affected men in the present families.
Clinical phenotypes
Number of
cases (%)
Latitude of
origin Parallel
30 Alive
Age at investigation
(years)*
Age at onset
(years)* Age at death (years)*
Asymptomatic 6 (7%) 6/6 6.4
1.9–10.8
(2–14)
--
Addison-only 6 (7%) 5/6 15.2
5.3–25
(5–34)
7.4
5.4–9.4
(4–10)
10
a
CALD 54 (62%) 39/54 22/49
# 16.5
13.9–19
(7–39)
10.9
9.1–12.7
(5–27)
24.7
b
19.8–29.6
(7–24)
AMN 14 (16%) 11/14 11/14 40.2
32.5–47.8
(20–53)
26.4
20.3–32.5
(15–42)
Unknown
Unknown 7 (8%) –
Total 87 (100%) 44/75 19.7
16.2–32.2
(2–53)
12.5
10.2–14.7
(4–42)
-
CALD: Cerebral form, AMN: Adrenomyeloneuropathy.
*Mean, CI 95%, (range). Means estimated as survival functions (see Figure 3).
aone case,
b16 cases.
#number of valid cases, 5 losses in follow up.
doi:10.1371/journal.pone.0034195.t002
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existence of distant common ancestors for contemporary patients.
The same phenomenon appeared in our sample.
In our sample, the proportions of missense, frameshift and
nonsense mutations were similar to those found worldwide
(http://www.x-ald.nl). In contrast, a possible cluster of mutations
at two amplicon regions, exons 2 and 8–9, was observed (Figure 1).
The occurrence of CALD in a girl with a skewed X-inactivation
in our case series deserves consideration. The present female
patient resembled the one reported by Hershkovitz et al [15]. Both
girls have clinical, biochemical and MRI abnormalities similar to
those seen in boys with CALD. Two important differences must be
stressed, however. Our patient did not have a positive family
history of X-ALD, nor an X chromosome deletion.
Skewing of inactivation is frequently observed in heterozygotes for
ABCD1 mutations, and it was found to correlate with neurological
manifestations [16]. As far as we know, skewing per se was never
related to CALD in a woman. The occurrence of CALD in our
patient points to the X chromosome bearing the c.1074–1075insA
mutation in ABCD1 to be the active one, rendering ‘‘the patient
totally deficient in ALDP and equivalent to an affected male’’ [15].
Our phenotype proportions in males seemed to differ from the
expected ones, reported in literature. In the present study, all efforts
to obtain a complete family history of up to three generations were
done, plus biochemical and molecular studies of the men alive. We
identified 87 affected men in 38 genealogies (including the de novo
pedigrees), or 2.2 cases per family, a rate similar to those found by
others in larger series [6]. However, our rates of CALD (62%) were
higher than the expected 45–57% [1,17,18]. We are aware that
underdiagnosis would be the best explanation to the present
numbers, moreover because only 6% of our series comprised
Addison-only disease (expected to be between 8 and 20%).
However, if underdiagnosis of AMN and Addison-only was
operating here, we would be unable to explain why the molecular
results obtained in male relatives studied after genetic counseling of
the nuclear family were near as those expected a priori. If the clinical
characterization of our sample was insufficient, a higher proportion
of carriers found by chance would be expected.
If the present observation of a high proportion of CALD in our
sample was correct, the hypothesis of an environmental factor
should be considered. Head trauma has been postulated as a risk
factor for the cerebral form in X-ALD [17], but we did not observe
such phenomena. Inflammation and altered immune responses are
present in CALD, whose demyelinating lesion is very similar to
those seen in multiple sclerosis (MS) [19,20]. Among other factors,
latitude is clearly related to MS prevalence, and environmental
modifiers which vary with latitude, such as ultraviolet radiation,
have been postulated to MS [21]. By analogy, we speculated if
differences in latitude could also be related to a higher prevalence
and/or natural history of CALD. Our data did not support this
association, though the small latitude range of the present
observation might have precluded a final conclusion.
We believe that further studies on X-ALD prevalence, mutation
patterns, natural history and clinical course after bone marrow
transplantation in countries outside Europe and USA are necessary.
This knowledge will further help the management of these families,
as well as may help the understanding of disease mechanisms.
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